ClinicalTrials.gg
RecruitingNCT07514780Updated Apr 23, 2026

To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers

A Phase 1 interventional study of JW0061 SAD and JW0061 MAD in Healthy, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This clinical study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation clinical trial to evaluate the safety, pharmacokinetic and pharmacodynamics of JW0061 following topical application in Korean and Caucasians healthy adults.

Read the detailed description

The study is divided into two parts:

  • Part 1 (Korean Healthy Adults): Consists of 5 cohorts each for Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages.
  • Part 2 (Caucasian Healthy Adults): Consists of 2 cohorts each for SAD and MAD stages to evaluate the drug in a different ethnic group.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight between 50.0 kg and 90.0 kg, and between 18.5 and 29.9 kg/m².
  • Determined to be healthy and eligible by the investigator based on medical history, physical examination, and clinical laboratory tests.
  • Capable of providing written and willing to comply with all study requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Presence of scalp conditions that may interfere with safety assessments.
  • History of within 5 years prior to screening.
  • History of or allergy to the study drug or its components.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Part 1: SAD

    Up to five cohorts (S1-S5) (n = 40). Conducted in healthy Korean adults.

    Drug: JW0061 SAD · Drug: Placebo

  • Experimental
    Part 1: MAD

    Up to five cohorts (M1-M5) (n = 40). Conducted in healthy Korean adults.

    Drug: JW0061 MAD · Drug: Placebo

  • Experimental
    Part 2: SAD

    Up to two cohorts (S6-S7) (n = 12). Conducted in healthy Caucasian adults.

    Drug: JW0061 SAD

  • Experimental
    Part 2: MAD

    Up to two cohorts (M6-M7) (n = 12). Conducted in healthy Caucasian adults.

    Drug: JW0061 MAD

Interventions

  • DrugJW0061 SAD

    Single ascending doses

    Also known as: JW0061

  • DrugJW0061 MAD

    Multiple ascending doses

    Also known as: JW0061

  • DrugPlacebo

    Matching placebo for JW0061

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events (TEAEs)

    Safety and tolerability will be assessed by monitoring the frequency and severity of Adverse Events (AEs). Adverse events are categorized into Pre-Treatment Adverse Events (PTAEs) and Treatment-Emergent Adverse Events (TEAEs).

    Time frame: SAD: From Screening(Day -28) up to Day 8, MAD: From Screening(Day -28) up to Day 28

  2. Skin Irritation Assessment - Subjective

    Evaluation of skin safety using participant-reported subjective irritation (itching, prickling, burning, stinging, and tightness).

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  3. Skin Irritation Assessment - Objective

    Evaluation of skin safety using investigator-observed objective irritation (erythema, dryness/scaling, folliculitis, edema, and papules).

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  4. Systolic Blood Pressure

    Systolic blood pressure will be measured in millimeters of mercury (mmHg). Any clinically significant abnormal findings will be collected as adverse events.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  5. Diastolic Blood Pressure

    Diastolic blood pressure will be measured in millimeters of mercury (mmHg). Any clinically significant abnormal findings will be collected as adverse events.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  6. Pulse Rate

    Pulse rate will be measured in beats per minute (bpm). Any clinically significant abnormal findings will be collected as adverse events.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  7. Body Temperature

    Body temperature will be measured in degrees Celsius (°C). Any clinically significant abnormal findings will be collected as adverse events.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  8. 12-lead ECG

    Safety is assessed through 12-lead ECG parameters, including heart rate, PR interval, QRS duration, QT interval, and QTcB. Clinically significant findings, such as rhythm abnormalities, are collected as adverse events.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  9. Shift from Baseline in Laboratory Test Results

    Laboratory test results are classified as normal, clinically non-significant abnormal, or clinically significant abnormal, and presented in a shift table from baseline. Measurements are performed using standard clinical laboratory methods.

    Time frame: SAD: From baseline (Day 1 pre-dose) up to Day 8, MAD: From baseline (Day 1 pre-dose) up to Day 28

  10. Physical Examination (Normal/Abnormal)

    Physical examination findings categorized as normal or abnormal based on a comprehensive assessment including medical history review, interview, inspection, palpation, percussion, and auscultation, as assessed by the investigator.

    Time frame: SAD: From Screening(Day -28) up to Day 8, MAD: From Screening(Day -28) up to Day 28

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital Clinical Trial Center
    Seoul, Seoul 110-744, South Korea
    Recruiting
    • SeungHwan Lee · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Apr 7, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514780
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 13, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Soyeon Jeong
Contact
soyoun1628@jwhealthcare.com
+82-2-840-6797
Inyoung Park
Contact
inyoung.park@jwhealthcare.com
+82-2-840-6887
Seung Hwan Lee
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion